

COMPANY PROFILE 2019
ANGELINI PHARMA



ANGELINI PHARMA

Angelini is a private, international group - leader in Healthcare and Well-being. Its effort is helping patients, physicians and caregivers in the fight against diseases. Angelini gives constant and foremost attention to the areas of **Pain and Inflammation, Mental Health and Infectious Diseases**.

Founded in Italy at the beginning of the 20th century, Angelini has activities in **18 countries** in the pharmaceutical industry, employs over **3,000 people** and has a turnover of almost **900 million euros**.

Angelini is an integrated pharmaceutical company with extensive and well-recognised **Research and Development** programmes, in addition to **world-class production facilities** and **international marketing** activities of key compounds and leading drugs in many sectors. Strategic partnerships with international companies complete and expand the geographical areas where Angelini operates.

In Italy and abroad, Angelini has a strong historical experience in the field of over-the counter (OTC) medications.

Over the years, the **Research and Development** teams at Angelini have identified several important molecules such as trazodone and benzydamine, and are currently involved in innovative research projects in the areas of diseases and disorders of the nervous system, pain and inflammation, with a particular commitment to the research of new treatments for the paediatric population.

The research at Angelini embraces public-private partnerships with recognised academic institutions and centres of global importance. The Scientific Network and Partnerships have both an important role in creating innovation.

Angelini's **production facilities** in Ancona (Finished Products), Aprilia (Raw Materials) and Casella are at the forefront of technologies, industry standards and environmental protection, thanks to the use and integration of renewable sources.

Angelini has offices in Italy, Spain, Portugal, Austria, Poland, Czech Republic, Slovakia, Hungary, Germany, Romania, Bulgaria, Slovenia, Croatia, Greece, Turkey, Russia, USA and Pakistan.

In line with its **international strategies**, Angelini has developed pathways for development in countries with high growth potential, with both targeted acquisitions and enhancement of existing structures.

Moreover, important strategic alliances with leading pharmaceutical groups with a global footprint allow the distribution of Angelini products worldwide.

To name a few, these include **Trittico** (trazodone, antidepressant), **Latuda** (lurasidone hydrochloride, antipsychotic), **Tantum** (benzydamine, anti-inflammatory), **Aulin** (nimesulide, anti-inflammatory analgesic), Vellofent (fentanyl, analgesic) and **Xydalba** (dalbavancin).

In the last 10 years, the percentage sales outside Italy has grown constantly, reaching about 50% of total pharma sales today.



ANGELINI AT A GLANCE

- **881** million € reported turnover (2018)
- **3,000** employees
- **18** countries with direct presence on the ground
- **Over 50** countries in which products are marketed
- **Over 40** commercial partners
- **3** production plants in Italy

Contact:

Pharma HQ External Communications

Fabio Pieroni +39 06 91045443 f.pieroni@angelini.it

Felicia Ridola +39 06 91045444 f.ridola@angelini.it